News Releases

- V2ACT Therapeutics™, LLC is a joint venture of Genelux Corporation and TVAX Biomedical, Inc. - V2ACT is a proprietary immuno-oncology modality composed of Olvi-Vec (oncolytic immunotherapy) and V-ACT (vaccine-enhanced adoptive cell therapy). - V2ACT capitalizes on: - Olvi-Vec as an ideal systemic

Genelux closes on first tranche of a convertible debt and warrant financing of up to $20M to fund the continued clinical development of Olvi-Vec, its lead oncolytic immunotherapy candidate SAN DIEGO, Sept. 25, 2020 /PRNewswire/ -- Genelux Corporation, a privately-held clinical-stage immunotherapy

- Treatment with olvimulogene nanivacirepvec (Olvi-Vec)-primed immunochemotherapy shows promising overall survival benefit in this heavily pretreated late-stage patient population - The majority of patients benefited from apparent reversal of platinum resistance with preserved or improved

-- Treatment with olvimulogene nanivacirepvec (Olvi-Vec)-primed immunochemotherapy shows objective response and progression-free survival clinical benefits well exceed historical comparisons and patients' own last prior therapy -- The majority of patients benefited from apparent reversal of

Distinguished Gynecologic Oncology Experts to Guide Olvi-Vec Development Efforts SAN DIEGO, June 4, 2020 /PRNewswire/ -- Genelux Corporation, a privately-held, clinical-stage immuno-oncology company, today announced that it has formed a Clinical Advisory Board (CAB) on gynecologic cancers that will

Continues Preparation of Registrational Trial of Olvi-Vec in the Treatment of Platinum-Refractory/Resistant Ovarian Cancer Patients SAN DIEGO, May 7, 2020 /PRNewswire/ -- Genelux Corporation, a privately-held, clinical-stage immunotherapy company, today announced the outcome of a Type C meeting